Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study.

ABSTRACT:

Objective

Current prevention and/or treatment options for respiratory syncytial virus (RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very expensive and requires multiple intramuscular injections over the RSV season. Here we present proof-of-concept data using nebulized palivizumab delivery as a promising new approach for the prevention or treatment of severe RSV infections, documenting both aerosol characteristics and pulmonary deposition patterns in the lungs of lambs.

Design

Prospective animal study.

Setting

Biosecurity Control Level 2-designated large animal research facility at the Murdoch Children's Research Institute, Melbourne, Australia.

Subjects

Four weaned Border-Leicester/Suffolk lambs at 5 months of age.

SUBMITTER: Rajapaksa AE 

PROVIDER: S-EPMC7466567 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature